

Cirtuvivint

Chemical Properties


CAS No. : 2143917-62-6

Formula: C₂₄H₂₅N₇O

Molecular Weight: 427.5

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Cirtuvivint (SM08502) is a potent, orally active CDC-like kinase (CLK) inhibitor useful for the study of arthritis.
Targets(IC50)	CDK
In vitro	Inhibiting serine and arginine-rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity, Cirtuvivint (SM08502) is associated with the inhibition of Wnt pathway-related gene and protein expression. Cirtuvivint induces the generation of splicing variants of Wnt pathway genes, suggesting that its mechanism for inhibiting gene expression includes effects on alternative splicing[1].
In vivo	Significantly inhibiting the growth of gastrointestinal tumors, orally administered Cirtuvivint (SM08502) decreases SRSF phosphorylation and Wnt pathway gene expression in xenograft mouse models[1].

Solubility Information

Solubility	DMSO: 6 mg/mL (14.04 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.34 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3392 mL	11.6959 mL	23.3918 mL
5 mM	0.4678 mL	2.3392 mL	4.6784 mL
10 mM	0.2339 mL	1.1696 mL	2.3392 mL
50 mM	0.0468 mL	0.2339 mL	0.4678 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Betty Y Tam, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. *Cancer Lett.* 2020 Mar 31;473:186-197.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481